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Abstract Background: Non-Hodgkin lymphoma (NHL) is often diagnosed after emergency
presentation, a route associated with poor survival and an indicator of diagnostic delay.
Accounting for around half of all NHLs, diffuse large B-cell lymphoma (DLBCL) is of partic-
ular interest since although it is potentially curable with standardised chemotherapy it can be
challenging to identify at an early stage in the primary care setting.
Patients and methods: Set within a socio-demographically representative United Kingdom
population of around 4 million people, data are from an established patient cohort. This
report includes all patients (18 years) diagnosed with DLBCL 2004e2011 (nZ 1660). Emer-
gency admissions were identified via linkage to Hospital Episode Statistics using standard
methods, and survival was examined using proportional hazards regression.
Results: Two out of every five patients were diagnosed following an emergency admission, and
this was associated with advanced disease and poor survival (p < 0.001). Among the 80% of
patients treated with curative chemotherapy, survival discrepancies emerged at the point of
diagnosis; the adjusted hazard ratio (emergency versus non-emergency) at one month being
4.0 (95% confidence interval 1.9e8.2). No lasting impact was evident in patients who survived
for 12 months or more.
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Conclusion: Emergency presentation impacts negatively on DLBCL survival; patients present-
ing via this route have significantly poorer outcomes than patients with similar clinical char-
acteristics who present via other routes.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cancer survival rates are reported to be poorer in Britain
than many other European countries, resulting in an
estimated 7000 avoidable premature deaths each year [1].
The evidence suggests that diagnostic delay is a major
contributor to these differences, and hence the promo-
tion of early diagnosis is being tackled through policy
guidance and targets, with progress being audited na-
tionally [2e6]. Nonetheless, despite some positive
changes, there is considerable scope for improvement [7].
Emergency presentation is often considered a crude
marker of diagnostic delay for cancers that commonly
present with early signs and symptoms [8,9]; the analysis
of routinely compiled health data confirming that this
route to diagnosis is associated with long intervals and
poorer outcomes [10]. Among haematological cancers
(lymphomas, myelomas and leukaemias), emergency
presentation is relatively common [10,11]. While this is
clearly the appropriate route for conditions like the
acute leukaemias, the reasons why a relatively large
proportion of patients with non-Hodgkin lymphomas
(NHL) present as an emergency and have poorer sur-
vival is less obvious.
As a group, NHLs are challenging to study since they
comprise a heterogeneous spectrum of cancers with
diverse patterns of onset, treatments and outcomes; the
pathways of patients diagnosed with incurable but
comparatively indolent subtypes, like follicular lym-
phoma and marginal zone lymphoma, tend to follow a
remitting-relapsing course with periods of observation
being interspersed with multiple lines of chemotherapy,
whereas those of patients with more aggressive subtypes
tend to dichotomise according to whether the cancer is
potentially curable or not [12,13]. In this context, diffuse
large B-cell lymphoma (DLBCL), which is the com-
monest haematological malignancy and accounts for
around half of all NHLs, is of particular interest since
although it is curable with standardised chemotherapy
administered over a 6e8 month period, patients who
present with advanced disease tend to do less well than
those diagnosed at an earlier stage [14e17].
In the general patient population, DLBCL 5-year
overall survival is now around 60%, disease/treatment-
related deaths being highest in the first few months
following diagnosis [14e16,18]. Focussing on deaths
occurring within 3 years of diagnosis, the present report
uses data from an established United Kingdom (UK)
patient cohort to examine the potential impact of
emergency presentation on outcome in patients with
DLBCL.
2. Methods
The study is set within the Haematological Malignancy
Research Network (HMRN: www.hmrn.org), a
population-based patient cohort instigated in 2004 to
generate ‘real world’ evidence-based data for research
and audit purposes [19]. HMRN’s catchment population
of around 4 million is socio-demographically similar to
that of the UK as a whole [20]. Patient care within
HMRN is provided by 14 hospitals, clinical practice
adheres to national guidelines and all diagnoses (over
2200 new patients annually) are made and coded to the
latest World Health Organisation (WHO) classification
[12,19,21] by clinical specialists at a single integrated
haematopathology laboratory (the Haematological Ma-
lignancy Diagnostic Service: www.hmds.info); which was
cited in the UK’s Cancer Reform Strategy as ‘the model
for delivery of complex diagnostic services’ [2].
HMRN operates with Section 251 support under the
National Health Service (NHS) Act 2006, and all pa-
tients have prognostic, full treatment and outcome data
collected to clinical trial standards. All HMRN patients
are ‘flagged’ for death at the national Medical Research
Information Service and are routinely linked to Hospital
Episode Statistics Admitted Patient Care (HES-APC)
data. Area-based population counts are sourced from
the Office for National Statistics; with the income
domain of the national index of deprivation being used
as a marker of socio-economic status [15,22].
The present report focusses on patients aged 18 years
or over who were newly diagnosed with de novo DLBCL
between September 2004 and March 2011; all of whom
were followed up for death for a minimum of 3 years.
Primary source information on cancer stage, perfor-
mance status, disease-associated systemic symptoms (B-
symptoms), nodal status and treatment were obtained
directly from medical records [15]. Following guidelines
outlined by NHS Digital, hospital admissions were
constructed from HES-APC. Using a similar approach
to the Routes to Diagnosis initiative [10], emergency
presentation was defined as an admission within 30 days
of diagnosis directly from the accident and emergency
(A&E) department (HES-APC admission method codes
21, 28), consultant-led outpatient clinic (code 24), bed
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Table 1
Patient and disease characteristics distributed by presentation route: diffuse large B-cell lymphomas diagnosed Sept 2004 to Mar 2011 and followed for 3 years.
Diagnoses by presentation route Deaths by presentation route Hazard ratio
(95% confidence
interval)b
Diagnoses (%) Non-emergency
(%)
Emergency (%) Chi-squareb Deaths (% of
all diagnoses)
Non-emergency
(% of non-emergency
presentations)
Emergency (%
of emergency
presentations)
Total 1660 (100) 1007 (100) 653 (100) 749 (45) 346 (34) 403 (62) 2.5 (2.2e2.9)
Sex Male 853 (51) 529 (53) 324 (50) 380 (45) 181 (34) 199 (61) 2.6 (2.1e3.2)
Female 807 (49) 478 (47) 329 (50) p Z 0.25 369 (46) 165 (35) 204 (62) 2.4 (2.0e3.0)
Age at diagnosis
(years)
<50 214 (13) 125 (12) 89 (14) 39 (18) 10 (8) 29 (33) 4.8 (2.4e9.9)
50e74 873 (53) 538 (53) 335 (51) 345 (40) 155 (29) 190 (57) 2.7 (2.2e3.3)
75þ 573 (35) 344 (34) 229 (35) p Z 0.64 365 (64) 181 (53) 184 (80) 2.6 (2.1e3.2)
Median (IQR) 69.9 (59.2e78.1) 69.2 (59.2e77.9) 70.6 (58.9e78.4) 74.8 (65.6e81.6) 75.6 (65.8e82.1) 74.3 (65.1e81.4)
Deprivation
(quintile)a
1, Least deprived 352 (21) 234 (23) 118 (18) 150 (43) 79 (34) 71 (60) 2.5 (1.8e3.5)
2 386 (23) 221 (22) 165 (25) 163 (42) 65 (29) 98 (59) 2.8 (2.0e3.8)
3 326 (20) 205 (20) 121 (19) 158 (48) 81 (40) 77 (64) 2.3 (1.7e3.2)
4 292 (18) 175 (17) 117 (18) 140 (48) 63 (36) 77 (66) 2.6 (1.8e3.6)
5, Most deprived 302 (18) 171 (17) 131 (20) p Z 0.08 136 (45) 57 (33) 79 (60) 2.5 (1.8e3.5)
Patient’s performance
statusa
0, Good 430 (26) 364 (36) 66 (10) 79 (18) 60 (16) 19 (29) 1.9 (1.2e3.2)
1 719 (43) 467 (46) 252 (39) 287 (40) 164 (35) 123 (49) 1.7 (1.3e2.1)
2 335 (20) 133 (13) 202 (31) 230 (69) 88 (66) 142 (70) 1.3 (1.0e1.7)
3 þ 4 Poor 152 (9) 33 (3) 119 (18) p < 0.001 137 (90) 28 (85) 109 (92) 1.5 (1.0e2.3)
B-symptoms Absent 919 (55) 610 (61) 309 (47) 368 (40) 180 (30) 188 (61) 3.0 (2.4e3.6)
Present 741 (45) 397 (39) 344 (53) p < 0.001 381 (51) 166 (42) 215 (62) 2.0 (1.7e2.5)
Nodal status Nodal 441 (30) 325 (35) 116 (21) 125 (28) 77 (24) 48 (41) 2.1 (1.4e3.0)
Extranodal 281 (19) 163 (18) 118 (21) 112 (40) 52 (32) 60 (51) 1.9 (1.3e2.8)
Nodal þ extranodal 758 (51) 438 (47) 320 (58) p < 0.001 379 (50) 170 (39) 209 (65) 2.5 (2.0e3.0)
Not assigned 180 81 99 133 (74) 47 (58) 86 (87) 2.7 (1.9e3.8)
Cancer stage I 258 (17) 200 (22) 58 (10) 51 (20) 35 (18) 16 (28) 1.7 (0.9e3.1)
II 302 (20) 216 (23) 86 (15) 86 (28) 47 (22) 39 (45) 2.6 (1.7e4.0)
III 233 (16) 169 (18) 64 (11) 88 (38) 55 (33) 33 (52) 2.1 (1.3e3.2)
IV 702 (47) 342 (37) 360 (63) p < 0.001 406 (58) 163 (48) 243 (68) 2.0 (1.6e2.4)
Not fully staged 165 80 85 118 (72) 46 (58) 72 (85) 2.4 (1.7e3.5)
International
Prognostic
Index (IPI)
Low 347 (26) 273 (33) 74 (15) 52 (15) 40 (15) 12 (16) 1.1 (0.6e2.1)
Low/intermediate 303 (23) 216 (26) 87 (18) 83 (27) 46 (21) 37 (43) 2.4 (1.5e3.7)
Intermediate/high 318 (24) 200 (24) 118 (24) 135 (42) 78 (39) 57 (48) 1.4 (1.0e2.0)
High 349 (26) 145 (17) 204 (42) p < 0.001 247 (71) 89 (61) 158 (77) 1.8 (1.4e2.4)
Not known 343 173 170 232 (68) 93 (54) 139 (82) 2.6 (2.0e3.3)
1st line chemotherapy
with curative intent
Yes 1346 (81) 883 (88) 463 (71) 468 (35) 249 (28) 219 (47) 2.1 (1.7e2.5)
No 314 (19) 124 (12) 190 (29) p < 0.001 281 (89) 97 (78) 184 (97) 2.5 (1.9e3.2)
Palliative/supportive 217 (13) 67 (7) 150 (23) 217 (100) 67 (100) 150 (100) 2.1 (1.6e2.9)
Localised disease 97 (6) 57 (6) 40 (6) p < 0.001 64 (66) 30 (53) 34 (85) 2.5 (1.5e4.0)
a Not known: deprivation (n Z 2), performance status (n Z 24).
b Hazard ratios were estimated using Cox regression.
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bureau (code 23) or following a request from a General
Practitioner (GP) (code 22).
All analyses were conducted using standard methods
in the statistical packages Stata 14.1 (StataCorp, Texas)
and R 3.2.2 (R Core Team, Vienna). Three-year survival
was examined using time-to-event analysis. Adjusted
survival curves were produced using the average
approach; using Cox proportional hazards regression,
survival curves were estimated for all possible combi-
nations of covariate values and a weighted mean of the
curves was calculated to adjust the mix among patients
presenting as an emergency to that of those presenting
via other routes [23]. The adjusted curve weights were
propensity scores; logistic regression, adjusting for all
covariates and their statistically significant interactions,
was used to predict each patient’s probability of pre-
senting as an emergency, before scaling the predicted
probabilities to the proportion of patients in each group.
3. Results
Of the 1660 patients diagnosed with DLBCL during the
study period, 653 (39%) presented as an emergency. No
statistically significant differences between those who
presented via this route and those who did not were
evident for gender, age at diagnosis and deprivation
(Table 1). However, scores for patient’s performance
status and symptom burden (B-symptoms), cancer stage
and nodal status, as well as the composite prognostic
index, were all significantly higher in the group that pre-
sented as an emergency than in the group that did not
(p < 0.001). Assignment of nodal status and cancer stage
in DLBCL usually requires a bone marrow biopsy as well
as a computed tomography (CT) and/or positron-emis-
sion tomography (PET) scan. In our data, 180 (11%)
patients did not have enough information to assign nodal
status and 165 (10%) could not be assigned a cancer stage,
the slightly lower number with missing stage reflected the
fact that a few of the 180 patients were assigned to stage
IV on the basis of biopsy detected bone marrow, liver or
lung involvement. For both parameters, lack of assign-
ment occurred more frequently in patients who presented
via the emergency route than among those presenting via
the non-emergency route; 15% and 8%, respectively, for
nodal status, and 13% and 8% for stage.
The pronounced tendency for patients presenting via
the emergency route to have more advanced disease
impacted on whether or not they were fit enough to be
treated with intensive chemotherapy with curative intent;
71% (n Z 463) of those presenting as an emergency
receiving such treatment, compared to 88% (nZ 883) of
those presenting via other routes (p< 0.001). Of the 1346
patients treated with potentially curative chemotherapy,
85% received standard R-CHOP
(rituximab þ cyclophosphamide, doxorubicin, vincris-
tine and prednisone), and the remainder were mainly
treated with R-CVP (rituximab þ cyclophosphamide,
vincristine and prednisone) or R-CODOX-M/R-IVAC
(rituximab þ vincristine, doxorubicin, cyclophospha-
mide, cytarabine, etoposide, ifosfamide, mesna and
methotrexate) [17]; no regimen differences were evident
by route of presentation. The 314 (19%) of patients who
were not treated intensively comprised a heterogeneous
group; most (n Z 217/314; 69%) were managed using a
palliative/supportive approach, the remaining 97 had
localised disease that was mainly treated with radio-
therapy. The proportion of patients receiving palliative/
supportive care was significantly higher among patients
presenting via the emergency route (Table 1).
During the 3 years following diagnosis, 749 (45%) of
the patients died. As might be expected, the cumulative
incidence (risk) of death among patients who presented
via the emergency route was almost twice (403/653, 62%)
that of those who presented via other routes (346/1007;
34%). This survival difference, which is evident within all
strata of Table 1, emerged at the point of diagnosis
(Fig. 1) and yielded an overall unadjusted hazard ratio
(HR) for the 3 year period of 2.5 (95% confidence interval
[CI] 2.2e2.9) (Table 1). Interestingly, within age strata the
strongest effect was seen among those who were diag-
nosed before the age of 50 years (HR 4.8, 95% CI
2.4e9.9).
The survival disparity between those who presented
via the emergency route and those who did not is as
evident among patients who were treated with intensive
chemotherapy as it is among all patients combined
(Fig. 1C and 1D). Table 2 presents conditional and cu-
mulative survival estimates (adjusted for cancer stage
and nodal involvement, patient’s age, deprivation, per-
formance status and B-symptoms) distributed by time
since diagnosis; the 1-month (30 day) HRs for all pa-
tients (n Z 1660; HR Z 3.9, 95% CI 2.7e5.6), those
treated with intensive chemotherapy (n Z 1346;
HR Z 4.0, 95% CI 1.9e8.2), and those who were
managed with supportive/palliative care (n Z 217;
HRZ 3.8, 95% CI 2.3e6.1) are broadly similar. Among
the 80% of patients who received intensive chemo-
therapy, this survival separation is retained throughout
the treatment period; the conditional HR estimates
show progressively smaller differences reaching 1.3 (95%
CI 0.9e1.9) during the 6e12 month period. Impor-
tantly, however, mode of presentation had no lasting
impact among patients who responded to chemotherapy
and survived for 12 months or more; the conditional
12e24 year HRs being 1.0 (95% CI 0.7e1.5) for those
treated with curative intent (Table 2).
The contribution of potentially confounding prog-
nostic factors (cancer stage, nodal status, age, perfor-
mance status, B-symptoms and deprivation) to the
survival dichotomy seen even among patients treated
curatively who present via different routes is demon-
strated in Fig. 2. Clearly, whilst such established risk
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factors explain some of the variation seen in the initial
months following diagnosis, they do not account for it all.
4. Discussion
Survival of patients diagnosed with DLBCL who pre-
sented via the emergency route was significantly worse
than that of patients who presented via other routes.
Whilst emergency presentation is the appropriate route
for several conditions and illnesses, including the acute
leukaemias, for the majority of cancers it is considered
to be a proxy for advanced disease and delayed diag-
nosis [8,9]. Two out of 5 patients in our population-
based cohort were diagnosed via this route and the
survival disparity, which emerged at the point of diag-
nosis, was not wholly explained by stage of disease,
performance status, symptom burden and area-based
deprivation. In this context, although our findings for
DLBCL confirm the association between emergency
presentation, advanced disease and outcome, they also
suggest that other unmeasured factors may have a role
to play. Importantly, however, the survival difference,
which was as striking among the 80% of patients who
were treated with intensive chemotherapy as among the
total patient group, did not extend beyond the first year.
This is the first population-based study to examine
the potential impact of emergency presentation on
survival among an unselected group of patients diag-
nosed with DLBCL, the commonest of the NHLs. The
paucity of ‘real-world’ information on clinically mean-
ingful NHL subtypes is primarily due to the complexity
of disease classification [12,24]; which means that na-
tional data are often reported for all NHL subtypes
combined. In England, for example, the Routes to
Diagnosis initiative found that around one in four
NHLs were diagnosed via the emergency route, which is
fewer than the two in five observed here for DLBCL
[10]. This difference is likely to reflect the heterogeneity
of NHLs which, in addition to aggressively presenting
cancers like DLBCL, Burkitt lymphoma and mantle cell
lymphoma, include incurable but comparatively indo-
lent subtypes such as follicular lymphoma and marginal
zone lymphoma, which tend to present less acutely [13].
That advanced disease is a poor prognostic factor for
most cancers, including DLBCL [16], is well established;
and as such, earlier diagnosis has been identified as key to
improving cancer outcomes in the UK [6,25]. In this
context, the National Cancer Patient Experience Survey
reported that around a third of patients with NHL
(aggressive and indolent subtypes combined) had three or
more pre-referral GP consultations; and many patients
have expressed general frustrations with the diagnostic
process [4,26e28]. Such difficulties are generally attrib-
uted to the symptoms of lymphoma, which can be vague,
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Fig. 1. KaplaneMeier survival curves and 95% confidence intervals (dotted lines) for patients with diffuse large B-cell lymphoma: total
patients (A), patients treated with curative intent (B), total patients stratified by mode of presentation (C) and curatively treated patients
stratified by mode of presentation (D).
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intermittent and frequently associated with self-limiting
conditions [29e31]. To our knowledge, only one small
study (n Z 278) has attempted to examine diagnostic
delay in the primary care setting, and no impact on sur-
vival was detected in patients diagnosed during
2002e2010 [30]. However, mode of presentation was not
examined and the study was restricted to patients who
were treated with intensive chemotherapy; interestingly,
patients were also younger and had less advanced disease
(63 years, 50% with a performance status of zero) than
similarly treated patients in our cohort (67.4 years, 32%
with a performance status of zero) [15].
Major strengths of our study include its large well-
defined catchment population, completeness of
ascertainment and world-class diagnostics. All lym-
phomas within the study area’s 14 hospitals were diag-
nosed and coded to the latest WHO oncology
classification at one of the largest integrated haemato-
pathology laboratories in Europe, which is regarded by
the UK’s National Institute for Health and Care
Excellence as the model for service delivery [2,3]. In
addition, unlike analyses based solely on administrative
databases, we were able to incorporate information on
key clinical parameters, including patient’s performance
status and cancer stage, into our investigations; enabling
us to show that patients presenting as an emergency had
poorer survival than those with similar clinical charac-
teristics who presented via other routes.
With respect to potential limitations, emergency
presentation is a proxy for what is likely to be a com-
plex underpinning set of events/variables, some of
which will be related to the cancer itself and some ofT
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Fig. 2. Average adjusted survival curve among patients treated
with curative intent. Survival curves were predicted from Cox
proportional hazards model adjusted for age, deprivation, per-
formance status, B symptoms and disease stage, and the average
adjusted curve is shown with the observed KaplaneMeier survival
curves for emergency and not emergency presentation.
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which will not. In this context, whilst socio-economic
patterning is frequently detected in cancers with strong
environmental/life-style risk factors and/or screening
programmes, relationships with haematological cancers
are less clear-cut. Within our UK population of 4
million, no socio-economic associations with incidence
for any haematological malignancy subtype have been
observed [20]; and although variations with area-based
measure of deprivation and survival have been detec-
ted for chronic myeloid leukaemia (a long-term condi-
tion controlled with daily oral therapy) [33], no evidence
of socio-economic patterning for DLBCL incidence or
outcome have been found [15]. Nonetheless other fac-
tors, such as travelling distance to hospital and the
presence of existing co-morbidities, may well have had
an important role to play in the findings presented in
this report [34]. Furthermore, it is important to note
that, in common with the national Routes to Diagnosis
study [10,32], emergency admissions from several
sources have been grouped together. In our data,
around 30% of emergency admissions to hospital were
directly requested by GPs, and a further 40% occurred
via A&E department; the latter comprising a complex
mix of self-presentations, as well as A&E referrals
initiated by GPs. In this context, the ability to link to
primary care databases would enable more effective
pathway mapping. Such routine linkage, which should
be possible in the future, could lead to increased un-
derstanding and better strategies to support earlier
cancer diagnosis.
In summary, patients diagnosed with DLBCL after
an emergency admission had poorer levels of fitness,
more advanced stage disease, and were less likely to be
treated with curative intent. Among the 80% of patients
treated curatively, the survival of those presenting via an
emergency route was significantly poorer than that of
patients with similar clinical characteristics who pre-
sented via other routes. This survival disparity emerged
at the point of diagnosis, but did not extend beyond the
first year. Given the curable nature of this cancer, stra-
tegies to support earlier diagnosis should be considered,
since even minor improvements in time to diagnosis
could lead to significant survival benefits in the longer
term.
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